Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Parkinson's Disease With Constipation

  • End date
    Dec 30, 2025
  • participants needed
  • sponsor
    Guangzhou First People's Hospital
Updated on 25 January 2022
dopamine agonists


Parkinson's disease(PD) may cause the autonomic nervous system's improper functioning, which is responsible for regulating the intestinal tract movement. A certain degree of degeneration of digestive system function can cause PD patients to constipation symptoms. Studies have shown that up to 63 percent of people with Parkinson's disease experience constipation. What is more, medications for PD, including levodopa and dopamine agonist, can also cause constipation. In recent years, an increasing number of studies have been conducted to investigate gut microflora and their influence on the central nervous system. Furthermore, some studies of Parkinson's disease have confirmed that gut microflora plays a vital role in the occurrence and development of Parkinson's disease.

The purpose of this study is to evaluate the efficacy and safety of fecal microbiota transplantation in the treatment of constipation symptoms in patients with Parkinson's disease receiving a steady dose of levodopa. We will also analyze intestinal flora diversity in patients with Parkinson's disease with constipation. The investigation of the gut microbiome may emerge as a new therapeutic measure to treat constipation associate with Parkinson's disease.

Condition Parkinson's Disease, Fecal Microbiota Transplantation
Treatment Fecal Microbiota Transplantation
Clinical Study IdentifierNCT04837313
SponsorGuangzhou First People's Hospital
Last Modified on25 January 2022


Yes No Not Sure

Inclusion Criteria

Between 18-75 years of age
Signed informed consent form
Clinical diagnosis of Parkinson's disease (according to 2016 edition of Chinese Parkinson's disease diagnostic criteria)
Parkinson's disease duration of 1 year or more
Hoehn & Yahr stage 1-4 (including)
Patients have following 2 or more symptoms, which appear for at least 6 months and exist in recent 3 months: A. at least 25% of defecation feel strenuous; B. At least 25% of defecation was not massive or hard; C. at least 25% of defecation had incomplete feeling; D. at least 25% of defecation had anorectal obstruction; E. at least 25% of defecation needed manual assistance; F. defecation less than 3 times a week, with or without abdominal pain
Patients are taking oral L-dopa (with or without Benserazide, carbidopa, and O-methyltransferase inhibitors) at least 4 weeks, and be able to tolerate a steady dose of dopamine agonists, monoamine oxidase B inhibitors, anticholinergics, and / or adamantine
Patients are taking stable dosage of anti-PD drugs, antidepressant drugs and antipsychotics for more than 1 month
Be able to tolerate the FMT infusion method such as endoscopy, colonoscopy, capsule, nasoduodenal tube insertion, etc
Be able to receive follow-up visit, follow-up examination and specimen collection on time

Exclusion Criteria

Patients with Parkinson's syndrome and Parkinsonism plus syndrome
History of cerebrovascular accident, brain injury, epilepsy and other brain injury
The "opening" stage was Hoehn & Yahr 5
Patient received neurosurgical intervention or stereotactic brain surgery for Parkinson's disease
Patients with organic lesions of digestive tract
Patients had major abdominal surgery
History of infectious diarrhea and took antibiotics in recent 2 weeks
Patients infected with Clostridium difficile and other pathogens
Patients with HIV or compromised immune system (such as congenital immunodeficiency or currently taking immunosuppressive drugs)
Patients with uncontrollable basic diseases of digestive system
Patients could not fully understand and sign the informed consent form
Patients who were not considered suitable for inclusion in the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note